LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

Search

AbCellera Biologics Inc

Ouvert

SecteurSoins de santé

3.6 1.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.51

Max

3.62

Chiffres clés

By Trading Economics

Revenu

48M

-8.9M

Ventes

36M

45M

Marge bénéficiaire

-19.942

Employés

562

EBITDA

22M

-18M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+98.86% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

160M

1.1B

Ouverture précédente

1.91

Clôture précédente

3.6

Sentiment de l'Actualité

By Acuity

76%

24%

318 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

AbCellera Biologics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 mars 2026, 20:38 UTC

Résultats

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mars 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10 mars 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mars 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mars 2026, 23:35 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mars 2026, 23:06 UTC

Résultats

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mars 2026, 22:51 UTC

Principaux Événements d'Actualité

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mars 2026, 21:39 UTC

Acquisitions, Fusions, Rachats

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mars 2026, 21:21 UTC

Résultats

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mars 2026, 21:15 UTC

Résultats

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mars 2026, 21:15 UTC

Acquisitions, Fusions, Rachats

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mars 2026, 21:14 UTC

Résultats

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mars 2026, 21:13 UTC

Résultats

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mars 2026, 21:12 UTC

Résultats

Franco-Nevada 4Q Rev $597.3M >FNV

10 mars 2026, 21:12 UTC

Résultats

Franco-Nevada 4Q EPS $1.90

10 mars 2026, 20:57 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mars 2026, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

10 mars 2026, 20:44 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mars 2026, 20:34 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

10 mars 2026, 20:34 UTC

Market Talk
Résultats

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mars 2026, 20:23 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mars 2026, 20:16 UTC

Résultats

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mars 2026, 20:14 UTC

Résultats

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mars 2026, 20:14 UTC

Résultats

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mars 2026, 20:13 UTC

Résultats

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mars 2026, 20:12 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparaison

Variation de prix

AbCellera Biologics Inc prévision

Objectif de Prix

By TipRanks

98.86% hausse

Prévisions sur 12 Mois

Moyen 7 USD  98.86%

Haut 7 USD

Bas 7 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

1.99 / 2.635Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

318 / 351Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat